论文信息 - Enhanced Differential Evolution Entirely Parallel Method for Biomedical Applications

Enhanced Differential Evolution Entirely Parallel Method for Biomedical Applications

A considerable enhancement is proposed for the Differential Evolution Entirely Parallel DEEP method developed recently. A new selection rule was implemented in order to increase the robustness of DEEP. To simplify the approach a population is not divided now into branches, instead of it, several oldest individuals are substituted with the same number of the best ones after the predefined number of iterations. The individuals are selected on the basis of the number of generations, in which they survived without any change. We demonstrate how the enhanced DEEP provides new solutions to problems with several objective functions.

[1] Jouni Lampinen,et al. A Trigonometric Mutation Operation to Differential Evolution , 2003, J. Glob. Optim..

[2] Konstantin Kozlov,et al. DEEP—differential evolution entirely parallel method for gene regulatory networks , 2011, The Journal of Supercomputing.

[3] John R Fulghum,et al. In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061 , 2004, Journal of Biological Chemistry.

[4] Victor E. Malyshkin,et al. Parallel computing technologies , 2011, The Journal of Supercomputing.

[5] Ann D. Kwong,et al. VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.

[6] John Reinitz,et al. Modeling of Gap Gene Expression in Drosophila Kruppel Mutants , 2012, PLoS Comput. Biol..

[7] Rainer Storn,et al. Differential Evolution – A Simple and Efficient Heuristic for global Optimization over Continuous Spaces , 1997, J. Glob. Optim..

[8] N. Butkiewicz,et al. SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.

[9] Dylan P. Hartley,et al. Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227) , 2008, Antimicrobial Agents and Chemotherapy.